BiotechTube
Trutino Biosciences

Trutino Biosciences

San Diego, United States· Est.
trutinobio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Trutino Biosciences is a private, preclinical biotech leveraging its On-Demand-Cytokine (ODC) platform to engineer targeted cytokine prodrugs (Zytokines) for cancer and autoimmune disorders. The company has achieved a significant milestone with FDA IND approval for its lead program and is the subject of an option-to-acquire agreement with Boehringer Ingelheim. With a lean team and a focus on initiating its first Phase I study in solid tumors by Q1 2025, Trutino is positioned at a critical inflection point, aiming to demonstrate the clinical potential of its localized cytokine activation approach.

OncologyAutoimmune Diseases

Technology Platform

On-Demand-Cytokine (ODC) platform for engineering systemically delivered, locally activated cytokine prodrugs (Zytokines/Zymokines) via protease-cleavable linkers and targeting motifs.

Opportunities

Validating the ODC platform in Phase 1 trials could unlock significant value through a full acquisition by Boehringer Ingelheim and enable expansion into autoimmune disease applications.
The large, underserved markets in immuno-oncology and autoimmunity provide a substantial addressable opportunity for safer, targeted cytokine therapies.

Risk Factors

The lead program faces high clinical development risk, as failure would undermine the core platform technology.
The company is also dependent on Boehringer Ingelheim's decision to exercise its acquisition option and operates in a competitive landscape with other companies developing conditionally activated biologics.

Competitive Landscape

Trutino competes in the growing field of conditionally activated cytokine therapies, alongside companies like CytomX Therapeutics, Xilio Therapeutics, Werewolf Therapeutics, and Alkermes' (now Mural Oncology) nemvaleukin alfa program. Differentiation hinges on the specific engineering of the prodrug linker, targeting mechanism, and ultimately, clinical safety and efficacy profiles.

More companies in Biologics / Biosimilars →More companies in United States →